Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.62 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934204 | 0.95 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7215128 | 0.86 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6933682 | 0.85 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4464755 | 0.84 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6932122 | 0.81 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL4459150 | 0.79 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6934771 | 0.79 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7216158 | 0.78 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6935858 | 0.78 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6932744 | 0.77 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-6610698-B2 | Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases | AMGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0948497-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024782-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | DPYD, IL6, IL1B | MAPK14 2062/4885MAPK13 2250/4885MAPK12 1502/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | MAPK14 1169/4885MAPK13 1577/4885MAPK12 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.